Skip to main content
SpringerLink
Log in

Risk Factors and Prevention, Including Hyperlipidemias

  • Chapter
Essential Cardiology

  • 2008 Accesses

Abstract

Cardiovascular disease is the leading cause of death in the United States for both men and women (1). However, great strides have been made in the field of preventive cardiology over the past decade, that, combined with the significant advances in revascularization technologies, have enhanced the clinician’s ability to manage patients across the spectrum of atherosclerosis, from subclinical coronary heart disease (CHD) to congestive heart failure. Additionally, advances in noninvasive and invasive imaging have improved the capacity to diagnose the presence and vulnerability of the atherosclerotic plaque. Hypertension, smoking, and dyslipidemia remain the major remediable risk factors for the development and progression of atherosclerosis. This chapter will briefly review the major risk factors for CHD, then place a special emphasis on the management of lipid disorders based on the 2001 iteration of guidelines from the US National Cholesterol Education Program (NCEP), which stress the management of low-density lipoprotein cholesterol (LDL-C) as the primary target of lipid therapy (2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Heart Association. Heart and stroke facts: 2004 statistical supplement. Dallas: American Heart Association, 2003.

    Google Scholar 

  2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.

    Article  Google Scholar 

  3. Swanson JR, Pearson TA. Screening family members at high risk for coronary disease. Why isn’t it done? Am J Prev Med 2001;20:50–55.

    CAS  Google Scholar 

  4. Chobanian AV, Bakris GL, Black HR, et al., and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560–2571.

    Article  PubMed  CAS  Google Scholar 

  5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997.

    Article  Google Scholar 

  6. Giovino GA. Epidemiology of tobacco use in the United States. Oncogene 2002;21:7326–7340.

    Article  PubMed  CAS  Google Scholar 

  7. Senti M, Elosua R, Tomas M, et al. Physical activity modulates the combined effect of a common variant of the lipoprotein lipase gene and smoking on serum triglyceride levels and high density lipoprotein cholesterol in men. Hum Genet 2001;109:385–392.

    Article  PubMed  CAS  Google Scholar 

  8. Jastrzebska M, Goracy I, Naruszewicz M. Relationships between fibrinogen, plasminogen activator inhibitor-1, and their gene polymorphisms in current smokers with essential hypertension. Thromb Res 2003;110:339–344.

    Article  PubMed  CAS  Google Scholar 

  9. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with CHD: a systematic review. JAMA 2003;290:86–97.

    Article  PubMed  Google Scholar 

  10. Kannel WB. Range of serum cholesterol values in the population developing CHD. Am J Cardiol 1995;76(9 Suppl): 69C–77C.

    Article  PubMed  CAS  Google Scholar 

  11. Gotto A, Pownall H. The Manual of Lipid Disorders: Reducing the Risk for Coronary Heart Disease, 3rd ed. Lippin-cott Williams & Wilkins, New York, 2003.

    Google Scholar 

  12. Fojo SS, Brewer HB. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J Intern Med 1992;231:669–677.

    Article  PubMed  CAS  Google Scholar 

  13. Segrest JT. The role of non-LDL-C:non-HDL particles in atherosclerosis. Current Diabetes Reports 2002;2:282–288.

    Article  PubMed  Google Scholar 

  14. Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004;3:717–724.

    Article  CAS  Google Scholar 

  15. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292–2300.

    Article  PubMed  CAS  Google Scholar 

  16. Pearson TA, Mensah GA, Alexander RW, et al. AHA/CDC scientific statement markers of inflammation and cardiovascular disease application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the american heart association. Circulation 2003;107:499–511.

    Article  PubMed  Google Scholar 

  17. Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute MI. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999;100:1016–1030.

    PubMed  CAS  Google Scholar 

  18. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–239.

    Article  PubMed  Google Scholar 

  19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 2,536 high risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7–22.

    Article  Google Scholar 

  20. Thompson PD, Lim D. Physical activity in the prevention of atherosclerotic CHD. Curr Treat Options Cardiovasc Med 2003;5:279–285.

    Article  PubMed  Google Scholar 

  21. Williams PT. The relationship of heart disease risk factors to exercise quantity and intensities. Arch Int Med 1998;158:237–245.

    Article  CAS  Google Scholar 

  22. Rothenbacher D, Hoffmeister A, Brenner H, Koenig W. Physical activity, coronary heart disease and inflammatory response. Arch Int Med 2003;163:1200–1205.

    Article  Google Scholar 

  23. Bays H, Dujovne C. Colesevelam: a nonsystemic lipid altering drug. Expert Opin Pharmaco Ther 2003;4:779–790.

    Google Scholar 

  24. Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998;279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  25. Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after MI in patients with average cholesterol levels. N Engl J Med 1996;335: 1001–1009.

    Article  PubMed  CAS  Google Scholar 

  26. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of CHD with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301–1307.

    Article  PubMed  CAS  Google Scholar 

  27. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with CHD: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.

    Article  Google Scholar 

  28. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with CHD and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357.

    Article  Google Scholar 

  29. Shepherd J, Blauw JG, Murphy MD, et al. The PROSPER Study Group. Pravastatin in elderly subjects at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623–1630.

    Article  PubMed  CAS  Google Scholar 

  30. Sever PS, Dahlof B, Poulter NR, et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–1158.

    Article  PubMed  CAS  Google Scholar 

  31. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1682–1690.

    Google Scholar 

  32. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106–107.

    Article  PubMed  CAS  Google Scholar 

  33. Bradford RH, Schear CL, Chremos AN. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modified plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia. Arch Int Med 1991;151:43–50.

    Article  CAS  Google Scholar 

  34. Phillips PS, Haas RH, Bannykh S, et al. Statin associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581–585.

    PubMed  Google Scholar 

  35. Laaksonen R. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77:851–854.

    Article  PubMed  CAS  Google Scholar 

  36. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003;107:3124–3128.

    Article  PubMed  Google Scholar 

  37. Rader JI, Calvert RJ, Habcock JN. Hepatic toxicity of unmodified and time-released preparations of niacin. Am J Med 1992;92:77–81.

    Article  PubMed  CAS  Google Scholar 

  38. Lee CH, Olson T, Evans RM. Lipid metabolism, metabolic diseases and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2001–2007.

    Google Scholar 

  39. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30:1280–1287.

    Article  PubMed  CAS  Google Scholar 

  40. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug therapy in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255–3261.

    Article  Google Scholar 

  41. Mosca L. Summary of the American Heart Association’s Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. Arterioscler Thromb Vasc Biol 2004;24:394–396.

    Article  PubMed  CAS  Google Scholar 

  42. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. Heart and Estrogen/Progestin Replacement Study (HERS Research Group). JAMA 1998;280:605–613.

    Article  PubMed  CAS  Google Scholar 

  43. Writing Group for the Women’s Health Initiative Investigators. Risks and benefit of estrogen plus progestin in healthy post menopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.

    Article  Google Scholar 

  44. Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among US adults. Obes Res 2003;11:1223–1231.

    Article  PubMed  Google Scholar 

  45. Pasanisi F, Contaldo F, de Simone G, Mancini M. Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis 2001;11:401–406.

    PubMed  CAS  Google Scholar 

  46. Bonora E, Zenere M, Branzi P, et al. Influence of body fat and its regional localization on risk factors for atherosclerosis in young men. Am J Epidemiol 1992;135:1271–1278.

    PubMed  CAS  Google Scholar 

  47. Tanko LB, Bagger YZ, Alexandersen P, et al. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation 2003;107:1626–1631.

    Article  PubMed  Google Scholar 

  48. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–359.

    Article  PubMed  Google Scholar 

  49. Grundy SM, Hansen B, Smith SC Jr, et al. American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551–556.

    Article  PubMed  Google Scholar 

  50. Grundy SM, Brewer HB Jr, Cleeman JI, et al. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–438.

    Article  PubMed  Google Scholar 

  51. Grundy SM. Inflammation, metabolic syndrome, and diet responsiveness. Circulation 2003;108:126–128.

    Article  PubMed  Google Scholar 

  52. Goodpaster BH, Katsiaras A, Kelley DE. Enhanced fat oxidation through physical activity is associated with improvement in insulin sensitivity and obesity. Diabetes 2003;52:2191–2197.

    Article  PubMed  CAS  Google Scholar 

  53. Hamdy O, Ledbury S, Mullooly C, et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003;26:2119–2125.

    Article  PubMed  Google Scholar 

  54. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes 2003;27:1437–1446.

    Article  CAS  Google Scholar 

  55. Morbidity and Mortality Weekly Report. Prevalence of diabetes and impaired glucose tolerance in adults-United States, 1999–2003;52:833–837.

    Google Scholar 

  56. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with CHD. A subgroup analysis of the 4S study. Diabetes Care 1997;20:614–620.

    Article  PubMed  CAS  Google Scholar 

  57. Sacks FM, Tonkin AM, Craven T, et al. CHD in patients with low LDL-C: benefits of pravastatin in diabetics and enhanced role for HDL-C and triglycerides as risk factors. Circulation 2002;105:1424–1428.

    Article  PubMed  CAS  Google Scholar 

  58. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5,963 people with diabetes: a randomized, placebo-controlled trial. Lancet 2003;361:205–216.

    Article  Google Scholar 

  59. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27:S68–S71.

    Article  Google Scholar 

  60. Goff DC Jr, Labarthe DR, Howard G, Russell GB. Primary prevention of high blood cholesterol concentrations in the United States. Arch Intern Med 2002;162:913–919.

    Article  PubMed  Google Scholar 

Recommended Reading

  1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program(NCEP). Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.

    Article  Google Scholar 

  2. Chobanian AV, Bakris GL, Black HR, et al., and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560–2571.

    Article  PubMed  CAS  Google Scholar 

  3. Gotto A, Pownall H. The manual of lipid disorders: reducing the risk for coronary heart disease (3rd ed.). Lippincott Williams & Wilkins, New York, 2003.

    Google Scholar 

  4. Pearson TA, Mensah GA, Alexander RW, et al. AHA/CDC Scientific Statement Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511.

    Article  PubMed  Google Scholar 

  5. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551–556.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Weill Medical College of Cornell University, New York, NY

    Antonio M. Gotto Jr. MD, DPhil (The Stephen and Suzanne Weiss Dean, Professor of Medicine)

  2. Baylor College of Medicine, USA

    John Farmer MD (Associate Professor of Medicine, Chief)

  3. Section of Cardiology, Ben Taub Hospital, Houston, TX

    John Farmer MD (Associate Professor of Medicine, Chief)

Authors
  1. Antonio M. Gotto Jr. MD, DPhil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Farmer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medicine, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY

    Clive Rosendorff MD, PhD, FRCP (Professor) (Professor)

  2. Veterans Affairs Medical Center, Bronx, NY

    Clive Rosendorff MD, PhD, FRCP (Professor) (Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Gotto, A.M., Farmer, J. (2005). Risk Factors and Prevention, Including Hyperlipidemias. In: Rosendorff, C. (eds) Essential Cardiology. Humana Press. https://doi.org/10.1007/978-1-59259-918-9_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-918-9_23

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-370-1

  • Online ISBN: 978-1-59259-918-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation